Table 1.
Clinical characteristics of the study population.
| Characteristics | MSKCC patients (n = 1,099) | TCGA patients (n = 556) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Age (years) | ||||
| Median | 67 | |||
| Range | 31–90 | |||
| <60 | 701 | 63.8 | 167 | 30.0 |
| ≥60 | 398 | 36.2 | 389 | 70.0 |
| Sex | ||||
| Female | 502 | 45.7 | 265 | 47.7 |
| Male | 597 | 54.3 | 291 | 52.3 |
| TMB | ||||
| Median | 6.1 | 2.8 | ||
| Range | 0.9–336.8 | 0.2–299.0 | ||
| Low (≤10 mut/Mb) | 905 | 82.3 | 471 | 84.7 |
| High (>10 mut/Mb) | 194 | 17.7 | 85 | 15.3 |
| Unknown | 1 | 0.1 | 0 | 0.0 |
| Primary tumor location | ||||
| Left | 760 | 309 | 55.6 | |
| Right | 325 | 193 | 34.7 | |
| Unknown | 14 | 54 | 9.7 | |
| Stage at diagnosis | ||||
| I | 39 | 3.5 | 99 | 17.8 |
| II | 129 | 11.7 | 202 | 36.3 |
| III | 267 | 24.3 | 160 | 28.8 |
| IV | 664 | 60.4 | 74 | 13.3 |
| Unknown | 0 | 0.0 | 21 | 3.8 |
| Overall survival (months) | ||||
| Median | 27.6 | 2.8 | ||
| Range | 0–292.9 | 0–137.4 | ||
| Unknown | 0 | 0.0 | 2 | 0.4 |
TMB, tumor mutation burden; MSKCC, Memorial Sloan Kettering Cancer Center; TCGA, The Cancer Genome Atlas.